PREP in Neurodegenerative Disorders
Stopping Alzheimer's and Parkinson's disease
We are studying the role of prolyl oligopeptidase (PREP, formerly known as POP) on disease progression and neuronal toxicity in neurodegenerative disorders with protein aggregation. These disorders include several serious diseases such as Alzheimer’s and Parkinson’s diseases, and several more rare neurodegenerative conditions. Based on PREP inhibitors, we are developing novel and disease-modifying drug therapies to stop neuronal death in Alzheimer's and Parkinson's diseases.
Interested in collaborating with us or investing in our novel PREP ligands? See the video below for more information!
NeuroPREP pitch fall 2020
This 5-minute video briefly outlines our research and provides details on how to progress the novel PREP ligands into clinical trials.
Recent news from PREP lab
A new drug candidate for Parkinson’s disease shows promise in early stages of drug development
Researchers at the University of Helsinki have developed novel compounds that reduce the accumulation of protein deposits in neurons in the...
Dissertation from PREP lab!
Our PhD student, M.Sc. Tommi Kilpeläinen, will defend his PhD thesis titled "Development and biological characterization of novel ligands for...
Neurodegenerative diseases Neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, affect the brains and other...
We are happy to share our research results. If you are interested in our publications but cannot find a copy, please do not hesitate to...
We are a dynamic group of researchers with a strong focus on finding novel disease modifying therapies for neurodegerative diseases...